{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:08:47Z","timestamp":1784117327800,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.breast.2020.10.015","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T13:56:14Z","timestamp":1604152574000},"page":"216-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0869-5751","authenticated-orcid":false,"given":"Michael J.","family":"Hale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7420-7512","authenticated-orcid":false,"given":"Jack","family":"Cuzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6999-2851","authenticated-orcid":false,"given":"Ivana","family":"Sestak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2020.10.015_bib1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the international breast cancer intervention study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.breast.2020.10.015_bib2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study and other national surgical adjuvant breast and bowel project investigators","volume":"90","author":"Fisher","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9122","key":"10.1016\/j.breast.2020.10.015_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"issue":"9122","key":"10.1016\/j.breast.2020.10.015_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)85011-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.breast.2020.10.015_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol [Internet]."},{"issue":"18","key":"10.1016\/j.breast.2020.10.015_bib6","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2020.10.015_bib7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis","volume":"27","author":"Smith","year":"2016","journal-title":"Ann Oncol [Internet]."},{"issue":"22","key":"10.1016\/j.breast.2020.10.015_bib8","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"Lacroix","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9880","key":"10.1016\/j.breast.2020.10.015_bib9","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet [Internet]."},{"issue":"9","key":"10.1016\/j.breast.2020.10.015_bib10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/1940-6207.CAPR-11-0380","article-title":"Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention","volume":"4","author":"Lin","year":"2011","journal-title":"Cancer Prev Res [Internet]."},{"issue":"4","key":"10.1016\/j.breast.2020.10.015_bib11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.breast.2020.10.015_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.breast.2020.10.015_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1055-9965.EPI-10-1240","article-title":"Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal women without hot flashes","volume":"20","author":"Emond","year":"2011","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"10.1016\/j.breast.2020.10.015_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvo-vaginal atrophy","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.breast.2020.10.015_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/gme.0b013e3181acb9ed","article-title":"Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors","volume":"17","author":"Huang","year":"2010","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.breast.2020.10.015_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bjc.2011.254","article-title":"Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies","volume":"105","author":"Endogenous Hormones and Breast Cancer Collaborative Group","year":"2011","journal-title":"Br J Canc"},{"issue":"12","key":"10.1016\/j.breast.2020.10.015_bib17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol [Internet]."},{"issue":"July","key":"10.1016\/j.breast.2020.10.015_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jsbmb.2013.08.010","article-title":"Menopausal hot flashes: mechanisms, endocrinology, treatment","volume":"142","author":"Freedman","year":"2014","journal-title":"J\u00a0Steroid Biochem Mol Biol [Internet]."},{"key":"10.1016\/j.breast.2020.10.015_bib19","first-page":"1","article-title":"Hot flush values of gonadotropins and estradiol in the menopause","author":"Arizanovi\u0107","year":"2018","journal-title":"Serbian Arch Med."},{"issue":"2","key":"10.1016\/j.breast.2020.10.015_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3816\/SCT.2006.n.004","article-title":"Dehydroepiandrosterone for the treatment of hot flashes: a pilot study","volume":"3","author":"Barton","year":"2006","journal-title":"Support Cancer Ther [Internet]"},{"issue":"10","key":"10.1016\/j.breast.2020.10.015_bib21","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/annonc\/mdn353","article-title":"Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer","volume":"19","author":"Hickey","year":"2008","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2020.10.015_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10549-007-9548-1","article-title":"Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy","volume":"107","author":"Cella","year":"2008","journal-title":"Breast Canc Res Treat"},{"issue":"7","key":"10.1016\/j.breast.2020.10.015_bib23","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/bjc.2013.116","article-title":"Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality","volume":"108","author":"Makubate","year":"2013","journal-title":"Br J Cancer [Internet]."},{"issue":"5","key":"10.1016\/j.breast.2020.10.015_bib24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/bjc.2013.464","article-title":"The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study","volume":"109","author":"McCowan","year":"2013","journal-title":"Br J Cancer [Internet]."},{"issue":"3","key":"10.1016\/j.breast.2020.10.015_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","article-title":"Tamoxifen, hot flashes and recurrence in breast cancer","volume":"108","author":"Mortimer","year":"2008","journal-title":"Breast Canc Res Treat"},{"issue":"12","key":"10.1016\/j.breast.2020.10.015_bib26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","article-title":"Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial","volume":"9","author":"Cuzick","year":"2008","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.breast.2020.10.015_bib27","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.2012.45.3068","article-title":"Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis","volume":"31","author":"Fontein","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2020.10.015_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10549-013-2792-7","article-title":"Symptoms of endocrine treatment and outcome in the BIG 1-98 study","volume":"143","author":"Huober","year":"2014","journal-title":"Breast Canc Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2020.10.015_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2014.57.6926","article-title":"Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial","volume":"33","author":"Stearns","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2020.10.015_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4048\/jbc.2018.21.1.37","article-title":"Endocrine treatment-related symptoms and patient outcomes in breast cancer: a meta-analysis","volume":"21","author":"Yoo","year":"2018","journal-title":"J\u00a0Breast Cancer."},{"issue":"9348","key":"10.1016\/j.breast.2020.10.015_bib31","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(02)11774-0","article-title":"Hot flushes","volume":"360","author":"Stearns","year":"2002","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.breast.2020.10.015_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e13567","article-title":"Persistent vasomotor symptoms and breast cancer in the Women\u2019s Health Initiative (WHI)","volume":"36","author":"Chlebowski","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2020.10.015_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/1055-9965.EPI-10-0998","article-title":"Relationship between menopausal symptoms and risk of postmenopausal breast cancer","volume":"20","author":"Huang","year":"2011","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"10.1016\/j.breast.2020.10.015_bib34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ejca.2012.08.030","article-title":"Menopausal symptoms and the risk of young-onset breast cancer","volume":"49","author":"Fei","year":"2013","journal-title":"Eur J Canc"},{"issue":"11","key":"10.1016\/j.breast.2020.10.015_bib35","first-page":"1333","article-title":"Menopausal vasomotor symptoms and the incident breat cancer risk in the Study of Women\u2019s Health across the Nation","volume":"27","author":"Hart","year":"2016","journal-title":"Canc Causes Contr"},{"issue":"4","key":"10.1016\/j.breast.2020.10.015_bib36","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ejca.2013.11.033","article-title":"Vasomotor menopausal symptoms are not associated with incidence of breast cancer in a population-based cohort of mid-aged women","volume":"50","author":"Johanneke Van Den Berg","year":"2014","journal-title":"Eur J Cancer [Internet]."},{"issue":"4","key":"10.1016\/j.breast.2020.10.015_bib37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis","volume":"27","author":"Smith","year":"2016","journal-title":"Ann Oncol [Internet]."},{"issue":"3","key":"10.1016\/j.breast.2020.10.015_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/SPV.0b013e3181d7e86e","article-title":"Systemic effects of vaginally administered estrogen therapy: a review","volume":"16","author":"Krause","year":"2010","journal-title":"Female Pelvic Med Reconstr Surg"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762030206X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762030206X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:43:23Z","timestamp":1760777003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762030206X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":38,"alternative-id":["S096097762030206X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2020.10.015","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2020.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}